Crescent Biopharma, Inc. - Common Stock (NQ:CBIO)

9.410 -0.300 (-3.09%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 5, 2026 Add to My Watchlist

Price and Volume

Volume	388,617
Open	9.830
Bid (Size)	9.390 (200)
Ask (Size)	9.450 (400)
Prev. Close	9.710
Today's Range	9.265 - 9.930
52wk Range	9.100 - 21.40
Shares Outstanding	64,532,091
Dividend Yield	5.10%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Today 7:30 EST

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma Announces Grants of Inducement Awards

January 30, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Performance

YTD	-15.1%	-15.1%
1 Month	-15.3%	-15.3%
3 Month	-24.3%	-24.3%
6 Month	-13.7%	-13.7%
1 Year	-40.4%	-40.4%

More News

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

January 05, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma Announces Grants of Inducement Awards

December 18, 2025

From Crescent Biopharma, Inc.

Via GlobeNewswire

The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today ↗

December 04, 2025

Via Stocktwits

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

December 04, 2025

From Crescent Biopharma, Inc.

Via GlobeNewswire

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

December 04, 2025

From Crescent Biopharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Via GlobeNewswire

Crescent Biopharma Announces Grants of Inducement Awards

November 17, 2025

From Crescent Biopharma

Via GlobeNewswire

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 06, 2025

From Crescent Biopharma

Via GlobeNewswire

Crescent Biopharma to Present at November Investor Conferences

November 05, 2025

From Crescent Biopharma

Via GlobeNewswire

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

November 04, 2025

From Crescent Biopharma

Via GlobeNewswire

Crescent Biopharma to Present at September Investor Conferences

August 28, 2025

From Crescent Biopharma

Via GlobeNewswire

This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

August 25, 2025

Via Benzinga

This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday ↗

August 11, 2025

Via Benzinga

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

July 31, 2025

From Crescent Biopharma

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 16, 2025

Via Benzinga

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

July 08, 2025

From Crescent Biopharma

Via GlobeNewswire

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 26, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 26, 2025

Via Benzinga

Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗

June 26, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 24, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 18, 2025

Via Benzinga

US Stocks Likely To Open Higher Despite Trump's 'Unconditional Surrender' Call: All Eyes On Powell As Experts Predict Inflation Will Limit Fed's Rate Cut Capacity ↗

June 18, 2025

Via Benzinga

Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket ↗

June 18, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 30, 2023

Via Benzinga

Frequently Asked Questions

Is Crescent Biopharma, Inc. - Common Stock publicly traded?

Yes, Crescent Biopharma, Inc. - Common Stock is publicly traded.

What exchange does Crescent Biopharma, Inc. - Common Stock trade on?

Crescent Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Crescent Biopharma, Inc. - Common Stock?

The ticker symbol for Crescent Biopharma, Inc. - Common Stock is CBIO on the Nasdaq Stock Market

What is the current price of Crescent Biopharma, Inc. - Common Stock?

The current price of Crescent Biopharma, Inc. - Common Stock is 9.410

When was Crescent Biopharma, Inc. - Common Stock last traded?

The last trade of Crescent Biopharma, Inc. - Common Stock was at 02/05/26 04:00 PM ET

What is the market capitalization of Crescent Biopharma, Inc. - Common Stock?

The market capitalization of Crescent Biopharma, Inc. - Common Stock is 607.25M

How many shares of Crescent Biopharma, Inc. - Common Stock are outstanding?

Crescent Biopharma, Inc. - Common Stock has 607M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.